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Background: We investigated the clinical significance of excision
repair cross-complementation group 1 (ERCC1), breast cancer sus-
ceptibility 1 (BRCA1), and class III -tubulin (TUBB3) expression
in thymic epithelial tumors.
Method: Fifty-six patients with thymic epithelial tumors were included
in this study. Tumors sections were stained by immunohistochemistry
for ERCC1, BRCA1, TUBB3, microvessel density, and p53.
Results: ERCC1, BRCA1, and TUBB3 were expressed in 48%,
50%, and 27%, respectively. The expression of ERCC1, BRCA1,
and TUBB3 was significantly correlated with the grade of malig-
nancy in thymic epithelial tumors. These biomarkers were closely
associated with p53 and microvessel density and were a prognostic
marker for predicting poor outcome. We also found that overexpres-
sion of ERCC1 and TUBB3 was associated with resistance to
platinum- and taxane-based chemotherapy.
Conclusion: An expression of ERCC1, BRCA1, and TUBB3 was
correlated strongly with each other and was significantly associated
with a poor outcome in thymic epithelial tumors. High-ERCC1 and
TUBB3 expressions might be associated with resistance to plati-
num- and taxane-based chemotherapy, respectively.
Key Words: ERCC1, BRCA1,  III-tubulin, Thymic epithelial
tumor, Platinum-based chemotherapy.
(J Thorac Oncol. 2011;6: 606–613)
Thymic epithelial tumors are broadly classified into thy-moma and thymic carcinoma. Thymic tumors represent
0.2 to 1.5% of all malignancies, and overall, it is an uncom-
mon malignancy with an incidence of 0.15 cases/100,000
populations.1 Tumors of the thymus are a heterogenous group
of tumors, ranging from low-grade thymomas to high aggres-
sive carcinomas. The World Health Organization (WHO)
published a new histological classification of thymic epithe-
lial tumors into three subgroups—i.e., low-risk thymomas
(types A, AB, and B1), high-risk thymomas (types B2 and
B3), and thymic carcinomas.2,3 Complete surgical resection
of the tumor offers the best chance of a favorable outcome in
patients with thymic epithelial tumor. Nevertheless, the ex-
tent of the disease at the time of presentation often precludes
complete surgical resection. Therefore, systemic chemother-
apy plays a very important role in the treatment of this
disease. Several researchers have described the efficacy of
platinum-based chemotherapy against thymic epithelial tu-
mors.4–6 Nevertheless, it is necessary to find biomarkers that
can predict clinical outcomes and treatment sensitivity among
patients with thymic epithelial tumor treated by platinum-
based chemotherapy.
Nucleotide excision repair (NER) has been described to
be involved in the repair of platinum-induced DNA damage.7
Several researchers had investigated the prognostic and predic-
tive significance of NER pathway biomarkers.8–10 Excision
repair cross-complementation group 1 (ERCC1) and breast can-
cer susceptibility 1 (BRCA1) are involved in NER system, and
these proteins have been known to be associated with resistance
to platinum-based chemotherapy.8–11 Microtubules are complex
polymers consisting of tubulin dimers (containing one -tubulin
and one -tubulin molecule) and a variety of microtubule-
associated proteins.12 The isotype composition of -tubulins has
been related to taxane-based chemotherapy responsiveness.12,13
In patients with non-small cell lung cancer (NSCLC), low/
negative expression of ERCC1 was described to be associated
with higher objective response and prolonged survival in pa-
tients treated by platinum-based chemotherapy.14 The overex-
pression of BRCA1 and class III -tubulin (TUBB3) was re-
ported to be strongly associated with poor outcome in patients
with NSCLC.11,15 Although the platinum- and taxane-based
chemotherapy has been administered to patients with unresect-
able thymic epithelial tumors,4–6 there are still no data about the
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evaluation of ERCC1, BRCA1, and  III-tubulin in thymic
epithelial tumors.
To elucidate the role of ERCC1, BRCA1, and TUBB3
expression in thymic epithelial tumors, we conducted an
immunohistochemical examination of these biomarkers in
primary site. In addition, these markers were correlated with
angiogenic marker such as microvessel density (MVD) and
cell cycle control (p53).
PATIENTS AND METHODS
Patients
Between October 2002 and February 2010, 64 consec-
utive patients with thymic epithelial tumors were analyzed in
the study. Of these patients, eight patients were excluded for
further studies because the tissue specimens were not avail-
able. Thus, a total of 56 patients (28 men and 28 women)
were eligible in the study. The study protocol was approved
by the institutional review board.
The age of the patients ranged from 29 to 80 years
(median age, 61 years). Thirty-eight of the 56 patients under-
went surgical resection, and the remaining 18 underwent only
percutaneous needle-core biopsy. All tumors were staged
according to Masaoka classification.16 In patients with surgi-
cal excision, the stage was determined by operative and
pathological findings. In patients with biopsy only, the stage
was determined by diagnostic imaging including computed
tomography and 2-[18F]-fluoro-2-deoxy-D-glucose positron
emission tomography. All surgical specimens were reviewed
and classified according to the WHO classification2,3 by an
experienced lung pathologist who was unaware of clinical or
imaging findings. According to Masaoka classification, 14
were in stage 1, 15 in stage II, 10 in stage III, and 17 in stage
IV (7 in stage IVa and 10 in stage IVb). For patients without
surgery, the histological classification was determined by
specimens obtained through needle-core biopsy. As the initial
treatment, 38 patients were treated with surgery, 14 chemo-
therapy, and four thoracic irradiation. The tumor size of
primary tumors ranged from 15 to 140 mm (median, 64 mm).
All tumors were regrouped into three subgroups: low-risk
thymomas (types A, AB, and B1), high-risk thymomas (types
B2 and B3), and thymic carcinomas. According to the WHO
classification, the tumors included 28 low-risk thymomas (6
type A, 17 type AB, and 5 type B1), 11 high-risk thymomas
(six type B2 and five type B3), and 17 thymic carcinomas.
Immunohistochemical Staining
Immunohistochemical staining was performed according
to the procedure described in the previous reports.9,15,17,18 The
following antibodies were used: a mouse monoclonal antibody
against ERCC1 (ABI2356; Abcam, Tokyo, Japan; 1.200 dilu-
tion); a mouse monoclonal antibody against BRCA1
(ABI16780; Abcam, Tokyo, Japan; 1.50 dilution); a mouse
monoclonal antibody against TUBB3 (MMS-435P; Convance,
California, 1.500 dilution); a mouse monoclonal antibody
against CD34 (Nichirei, Tokyo, Japan,1.800 dilution); and a
mouse monoclonal antibody against p53 (D07; DAKO, 1.50
dilution).
The ERCC1 and BRCA1 were assessed semiquantita-
tively by estimating the percentage of tumor cells with
positive nuclear and/or cytoplasmic staining on whole tumor
slides (0 no staining, 0.1 positive staining in 1–9% of the
tumor cells, 0.5  positive staining in 10–49% of the tumor
cells, and 1  positive staining in 50% of the tumor cells).
The staining intensity was also evaluated in a semiquantita-
tive method representing the average intensity of the stained
tumor cells (0  no staining, 1  weak staining, 2 
moderate staining, and 3  strong staining). The proportion
and intensity scores were then multiplied to obtain a total
score, which ranged from 0 to 3 (H score).9,17
TUBB3 was also assessed by semiquantitative H score.
 III-tubulin tumor staining (cytoplasm) intensity was graded
on a scale of 0 to 2 using adjacent nonmalignant cells as a
reference. The percentage of positive tumor cell was evalu-
ated, and a area proportion score was attributed (0 if 0%, 0.5
if 1–9%, 1 if 10–24%, 2 if 25–49%, 3 if 50–74%, and 4 if
75%). This proportion score was then multiplied by the
staining intensity to obtain a final semiquantitative H score
with a range of 0 to 8.15
The number of CD34-positive vessels was counted in
four selected hot spots in a X 400 field (0.26 mm2 field area).
MVD was defined as the mean count of microvessels per 0.26
mm2 field area.18
For p53, microscopic examination for the nuclear reac-
tion product was performed and scored. According to previ-
ous report,18 p53 expression in more than 10% of tumor cells
was defined as high expression. Expression of Bcl-2 was
considered to be positive if there was staining of area of the
epithelial component of the tumor.
Sections were assessed using a light microscopic in a
blinded fashion by at least two of the authors.
Response Evaluation
We used the Response Evaluation Criteria in Solid
Tumors to assess response to chemotherapy.19 Response
based on target (and nontarget lesions) was defined as fol-
lows: complete response, disappearance of all target (nontar-
get) lesions; partial response (PR), 30% reduction in size
(or disappearance of one or more nontarget lesions); stable
disease (SD), less than 30% decrease and less than 20%
increase in size (or the persistence of one or more nontarget
lesions); and progressive disease (PD), more than 20% in-
crease in size (or the appearance of new nontarget lesions
and/or progression of existing nontarget lesions). The overall
response was defined as the best response recorded from the
start of treatment until disease progression or recurrence,
confirmed by repeated assessments performed no less than 4
weeks after the criteria for response were first met.
Statistical Analysis
Probability values of less than 0.05 indicated a statis-
tically significant difference. Fisher’s exact test was used to
examine the association of two categorical variables. Corre-
lation of different variables was analyzed using the nonpara-
metric Spearman’s rank test. The Kaplan-Meier method was
used to estimate survival as a function of time, and survival
difference was analyzed by the log-rank test. Statistical anal-
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ERCC1, BRCA1, TUBB3, CD34, and p53 immunohis-
tochemical staining was evaluated for the 56 primary lesions.
Figure 1 represents the immunohistochemical findings of
ERCC1, BRCA1, and TUBB3.
ERCC1, BRCA1, and TUBB3 were expressed in 48%
(27/56), 50% (28/56), and 27% (15/56) of thymic epithelial
tumors with a median H score of 0.50, 0.30, and 1.00,
respectively. The values of cutoff point of ERCC1, BRCA1,
and TUBB3 were 0.50, 0.30, and 1.00, respectively. A pos-
itive rate of ERCC1, BRCA1, and TUBB3 was recognized in
3% (1/28), 14% (4/28), and 3% (1/28) of low-risk thymomas;
82% (9/11), 73% (8/11), and 27% (3/11) of high-risk thymo-
mas; and 100% (17/17), 94% (16/17), and 65% (11/17) of
thymic carcinomas, respectively. According to WHO classi-
fication, the mean H score of ERCC1, BRCA1, and TUBB3
was 0.16  0.05, 0.21  0.09, and 0.61  0.15 in low-risk
thymomas; 1.06  0.13, 0.80  0.21, and 1.36  0.36 in
high-risk thymomas; and 1.53  0.15, 1.83  0.24, and
2.94  0.55 in thymic carcinomas, respectively, demonstrat-
ing significant differences between the three groups of these
biomarkers (Figure 2). Significant correlation was found
between the mean H score of ERCC1, BRCA1, and TUBB3
and the grading of WHO classification, and between the mean
H score of these biomarkers and the grading of Masaoka
classification (Supplementary Figure A).
The median number of CD34 was 26 (range: 8–45),
and the value of cutoff point was 26. High expression of
CD34 was seen in 46% (26/56). High expression of p53 was
recognized in 38% (21/56).
Demographics of Patients According to ERCC1,
BRCA1, and TUBB3
The demographic result of the patients according to these
biomarkers is listed in Table 1. In the analysis, according to
ERCC1 expression, gender, histology, BRCA1, TUBB3, MVD,
and p53 yielded a statistically significant positive correlation. In
BRCA1 expression, histology, ERCC1, TUBB3,MVD, and p53
yielded a statistically significant positive correlation. In TUBB3
expression, gender, histology, ERCC1, BRCA1, and p53
yielded a statistically significant positive correlation.
Survival Analysis in Thymic Epithelial Tumors
Median follow-up time for all patients was 34.5 months
(range, 8.0–92.0 months). The 5-year survival rate was 70.2%,
and the median survival time was not reached. Fourteen of 56
patients died because of PDs. In thymic epithelial tumors (n 
56), the 5-year survival rates of the ERCC1-positive and
ERCC1-negative patients were 30.6% and 100%, respectively,
(p  0.0001), those of BRCA1 positive and BRCA1 negative
were 43.4% and 96.4%, respectively, (p 0.0001), and those of
TUBB3 positive and TUBB3 negative were 20.3% and 86.5%,
respectively, (p 0.0001) (Figure 3). Moreover, the numbers of
death in the ERCC1-positive (n  27) and ERCC1-negative
patients (n 29) were 14 and 0, respectively, those of BRCA1-
positive (n  28) and BRCA1-negative patients (n  28) were
13 and 1, respectively, and those of TUBB3-positive (n  15)
and TUBB3-negative patients (n  41) were 9 and 5, respec-
tively. In thymoma (n  39), the 5-year survival rates of the
ERCC1-positive and ERCC1-negative patients were 60.0% and
100%, respectively, (p 0.0114), those of BRCA1 positive and
BRCA1 negative were 50.0% and 97.1%, respectively, (p 
0.0469), and those of TUBB3 positive and TUBB3 negative
were 20.3% and 86.5%, respectively, (p  0.1062) (Figure 3).
Univariate analyses of overall survival in thymic epithelial
tumors and thymomas were listed in Table 2 and Table 3,
respectively. Univariate analyses of thymic epithelial tumors
demonstrated that a statistically significant difference in the
overall survival was observed in tumor size, histology, ERCC1,
BRCA1, TUBB3, MVD, and p53 and those of thymomas
showed that the expression of ERCC1, BRCA1, and p53 was
significantly associated with poor outcome.
Platinum-Based Chemotherapy Response
According to ERCC1, BRCA1, and TUBB3
We investigated the relationship between the tumor
response and the expression of ERCC1, BRCA1, and TUBB3
in patients with thymic epithelial tumors treated by platinum-
based chemotherapy. The demographic result of the 17 pa-
tients who received platinum-based chemotherapy is listed in
Table 4. In 17 patients, no statistically significant difference
FIGURE 1. Immunohistochemical staining of excision repair cross-complementation group 1 (ERCC1), breast cancer suscepti-
bility 1 (BRCA1), and class III -tubulin (TUBB3) in thymic carcinoma. A, ERCC1 is stained in nuclei (H score, 3). B, BRCA1 is
stained in nuclei (H score, 3). C, TUBB3 is stained in cytoplasm (H score, 6).
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in the mean scoring of ERCC1, BRCA1, and TUBB3 was
observed between responder (PR) and nonresponder (SD/
PD). Nevertheless, the mean scoring of ERCC1 and TUBB3
tended to be lower in responder, when compared with non-
responder. In the analysis of the 14 patients treated by
carboplatin plus paclitaxel, a statistically significant differ-
ence in the mean scoring of ERCC1 and TUBB3 expression
was recognized between responder (PR) and nonresponder
FIGURE 2. Mean H score of excision repair cross-complementation group 1 (ERCC1), breast cancer susceptibility 1 (BRCA1),
and class III -tubulin (TUBB3) according to World Health Organization (WHO) classification. A, Mean (and standard devia-
tion) H scoring of ERCC1 was 0.16  0.05 in low-risk thymomas, 1.06  0.13 in high-risk thymomas, and 1.53  0.15 in
thymic carcinomas, demonstrating significant differences between the three groups (low risk versus high risk, p  0.0001 and
high risk versus thymic carcinoma, p  0.0499). B, Mean (and standard deviation) H scoring of BRCA1 was 0.21  0.09 in
low-risk thymomas, 0.80  0.21 in high-risk thymomas, and 1.83  0.24 in thymic carcinomas, demonstrating significant
differences between the three groups (low risk versus high risk, p  0.0065; high risk versus thymic carcinoma, p  0.0063).
C, Mean (and standard deviation) H scoring of TUBB3 was 0.61  0.15 in low-risk thymomas, 1.36  0.36 in high-risk thy-
momas, and 2.94  0.55 in thymic carcinomas, demonstrating significant differences between the three groups (low risk ver-
sus high risk, p  0.0241; high risk versus thymic carcinoma, p  0.0425).
TABLE 1. Patient’s Characteristics According to Biomarkers
Parameters












(n  41) p
Age (65/65 yr) 16/11 20/9 0.57 17/11 20/8 0.57 9/6 28/13 0.75
Gender (male/female) 18/9 10/19 0.03 17/11 11/17 0.18 11/4 15/26 0.01
Tumor size (64/64 mm) 10/17 19/10 0.06 12/16 17/11 0.28 6/9 23/18 0.36
Histology (thymoma/thymic carcinoma) 10/17 29/0 0.01 12/16 27/1 0.01 4/11 35/6 0.01
ERCC1 (positive/negative) — — — 24/4 3/25 0.01 15/0 12/29 0.01
BRCA1 (positive/negative) 24/3 4/25 0.01 — — — 14/1 14/27 0.01
Class III -tubulin (positive/negative) 15/12 0/29 0.01 14/14 1/27 0.01 — — —
MVD (CD34) (positive/negative) 20/7 6/23 0.01 21/7 7/21 0.01 10/5 16/25 0.07
P53 (positive/negative) 19/8 2/27 0.01 20/8 1/27 0.01 11/4 9/32 0.01
ERCC1, excision repair cross-complementation group 1; BRCA1, breast cancer susceptibility 1; MVD, microvessel density.
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(SD/PD) but not BRCA1 (Figure 4). The efficacy of this
regimen yielded a response rate of 35.7% (95% confidence
interval, 10.6–60.8%). No statistically significant difference
in the response analysis according to MVD and p53 expres-
sion was observed between responder and nonresponder.
Next, we also examined the survival analysis in the 17
patients. In this population (n  17), a median H score of
ERCC1, BRCA1, and TUBB3 was 1.00, 2.00, and 3.00,
respectively. The values of cutoff point of ERCC1, BRCA1,
and TUBB3 were 1.00, 2.00, and 3.00, respectively. Never-
theless, no statistically significant difference was recognized
in the outcome according to the expression of ERCC1,
BRCA1, and TUBB3.
DISCUSSION
To our knowledge, this is the first study to evaluate the
biomarkers for chemotherapy responsiveness in thymic epi-
thelial tumors. The results of the study demonstrated that the
expression of ERCC1, BRCA1, and TUBB3 was significantly
associated with a poor outcome and tended to increase from
low-grade to high-grade thymic epithelial tumors. These
biomarkers were closely associated with cell cycle control
and angiogenesis and were useful for predicting poor out-
come. We found that the overexpression of ERCC1 and
TUBB3 was associated with resistance to platinum- and
taxane-based chemotherapy in patients with unresectable thy-
mic epithelial tumors.
FIGURE 3. Overall survival curve of all patients (n  56) according to (A) excision repair cross-complementation group 1
(ERCC1), (B) breast cancer susceptibility 1 (BRCA1), and (C) class III -tubulin (TUBB3), and thymoma (n  39) according to
(D) ERCC1, (E) BRCA1, and (F) TUBB3.








Age (65/65 yr) 1.01 0.31–3.29 0.6923
Gender (male/female) 3.06 0.98–9.59 0.1857




ERCC1 (positive/negative) 13.8 4.66–41.1 0.0001




MVD (CD34) (positive/negative) 7.37 2.33–23.3 0.0034
P53 (positive/negative) 14.3 4.06–50.1 0.0001
ERCC1, excision repair cross-complementation group 1; BRCA1, breast cancer
susceptibility 1; MVD, microvessel density.
TABLE 3. Univariate Survival Analysis in Thymomas
Parameters Univariate Analysis, p
Age (65/65 yr) 0.5069
Gender (male/female) 0.4450
Tumor size (64/64 mm) 0.1410
ERCC1 (positive/negative) 0.0114
BRCA1 (positive/negative) 0.0469
Class III -tubulin (positive/negative) 0.1062
MVD (CD34) (positive/negative) 0.1655
P53 (positive/negative) 0.0353
ERCC1, excision repair cross-complementation group 1; BRCA1, breast cancer
susceptibility 1; MVD, microvessel density.
Kaira et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer610
ERCC1 is a component of the NER complex, and it is
responsible for the 5 incision required for the removal of DNA
adducts that are the basis for platinum cytotoxicity.20 In several
clinical studies, it has been reported that ERCC1 expression in
various types of neoplasm, including ovarian, colorectal, gastric,
esophageal cancers, and NSCLC, is associated with clinical
resistance to platinum agents.14,21–24 The International Adjuvant
Lung Cancer Biology Trial Bio study demonstrated that
ERCC1-negative expression was a significantly prolonged out-
come in patients with NSCLC who received adjuvant cisplatin-
based chemotherapy, but ERCC1-positive expression was iden-
tified as a prognostic marker of longer survival in patients with
NSCLC without platinum-based chemotherapy.9 Nevertheless,
recent work suggests that ERCC1 expression is predictive in
adenocarcinoma but not in other types of lung cancer.25 In this
study, ERCC1-positive expression was identified as a marker of
poor outcome in 39 patients with thymoma. Almost patients
(n  36) were not treated by platinum-based chemotherapy.
Moreover, the positive rate of ERCC1 expression was signifi-
cantly correlated with the grade of malignancy in thymic epi-
thelial tumors. Considering that ERCC1-positive expression was
a poor prognostic marker in population without platinum-based
chemotherapy, the expression profile of ERCC1 in thymoma
may be different from that of NSCLC. Nevertheless, the exact
underlying mechanism is unknown. On the other hand, the
survival of 17 patients treated by platinum-based chemotherapy
was not significantly different between ERCC1-positive and
ERCC1-negative expression. As our population was a small
sample size, there is a limitation in the survival analysis among
17 patients. Because there is only our study assessing the
ERCC1 expression in thymic epithelial tumors, further investi-
gation is warranted.
















1 58 F Thymoma A III CODE PR 9 56 Died
2 52 F Thymoma B3 IVb CODE PR 6 20 Alive
3 50 M Thymic ca. C INb CODE SD 6 8 Died
4 58 F Thymoma B1 IVa CP SD 9 47 Alive
5 32 M Thymic ca. C IVb CP SD 3 10 Died
6 66 M Thymic ca. C IVb CP SD 8 23 Died
7 61 F Thymic ca. C IVb CP PR 8 17 Died
8 64 M Thymic ca. C IVa CP SD 32 34 Died
9 80 M Thymic ca. C IVa CP SD 3 10 Died
10 57 M Thymic ca. C IVa CP SD 28 52 Alive
11 46 M Thymic ca. C IVb CP PD 1 3 Died
12 29 M Thymic ca. C IVb CP PR 5 20 Died
13 56 M Thymic ca. C IVb CP PR 8 26 Died
14 61 F Thymic ca. C IVa CP PR 7 10 Died
15 66 F Thymic ca. C IVb CP SD 6 8 Died
16 68 M Thymic ca. C III CP SD 6 8 Alive
17 70 M Thymic ca. C IVa CP SD 6 8 Alive
CTx, chemotherapy; PFS, progression-free survival; OS, overall survival; Thymic ca., thymic carcinoma; PR, partial response; SD, stable disease; PD, progressive disease;
CODE, cisplatin, vincristine, doxorubicin, and etoposide; WHO, World Health Organization, CP, carboplatin plus paclitaxel.
FIGURE 4. Relationship between tumor response and the expression of excision repair cross-complementation group 1
(ERCC1) (A), breast cancer susceptibility 1 (BRCA1) (B), and class III -tubulin (TUBB3) (C) in 14 patients with thymic epithelial
tumors treated by carboplatin plus paclitaxel. Analysis of the 14 patients treated by carboplatin plus paclitaxel demonstrated
that statistically significant difference in mean scoring of ERCC1 (p  0.0454) and TUBB3 (p  0.0397) expression was recog-
nized between responder and nonresponder but not BRCA1 (p  0.8622).
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BRCA1 plays a central role in DNA repair, and de-
creased BRCA1 mRNA expression caused cisplatin hyper-
sensitivity in vitro.26 Recent study demonstrated that the
overexpression of BRCA1 mRNA was strongly associated
with poor survival in patients with NSCLC, and BRCA1 is
closely related to ERCC1.27 The result of this study also
indicated that BRCA1-positive expression was related to poor
outcome and ERCC1 expression in thymic epithelial tumors.
The positive rate of BRCA1 according to WHO was similar
to that of ERCC1, when compared with TUBB3.
High expression of TUBB3 has been associated with
low response rates to taxane-containing regimens and with
poor outcome in patients with NSCLC, breast, ovarian, and
gastric cancer, and with cancers of unknown primary site.28
Many in vitro studies also demonstrated that high levels of
TUBB3 expression are related with paclitaxel resistance in
human cancer cell lines (lung, ovarian, prostate, and breast).28
Nevertheless, there is still no data about the expression of
TUBB3 in thymic epithelial tumors. Our study indicated that
high expression of TUBB3 was closely correlated either with
low response rates in patients treated with regimens contain-
ing taxanes or with reduced survival in patients with thymic
epithelial tumors. Koh et al.15 compared TUBB3 with
ERCC1 expression in resected NSCLC without adjuvant
chemotherapy, and the results of their study indicated that
TUBB3 expression was a worse prognostic factor than
ERCC1 expression. As our study includes 17 patients who
received platinum- and taxane-based chemotherapy and
thymic epithelial tumors are a heterogenous group of
neoplasms, the results of our study may not be similar to
those of their study.
This study also evaluated relationship between re-
sponse and the expression of ERCC1, BRCA1, and
TUBB3 in 17 patients treated by platinum-based chemo-
therapy. Of these 17 patients, 14 patients received the
combination chemotherapy of carboplatin plus paclitaxel.
Interestingly, the expression of ERCC1 and TUBB3 was
significantly lower in patients with responder than those
with nonresponder. Our results suggest that ERCC1 and
TUBB3 expression could be a resistant marker for plati-
num- and taxane-based chemotherapy in patients with
unresectable thymic epithelial tumors. BRCA1 may be not
appropriate as a predictor of response in patients with
thymic epithelial tumors. The results of in vitro study also
demonstrated that thymic carcinoma cells overexpressing
ERCC1 were resistant to platinum agent. In this study, no
statistically significant difference was recognized in the
survival analysis according to the expression of ERCC1
and TUBB3. Because of a small sample size, further
investigation in a large-scale study is warranted. In the
treatment for unresectable thymic epithelial tumors, almost
physicians select platinum-based chemotherapy as first-
line treatment. Nevertheless, it may be difficult to design
prospective studies including biomarkers as predictive
values in the unresectable thymic epithelial tumors, be-
cause of the low incidence of this disease. Such as our
retrospective study, therefore, it is important to investigate
the biological correlation of chemotherapy response in
unresectable thymic epithelial tumors.
This study has several limitations. One of the limita-
tions is that our sample size was small, including a heterog-
enous group of tumors. Thymic epithelial tumors are rare
neoplasms, thus a larger, multicenter cohort study is war-
ranted. Another limitation is that this study includes spec-
imens obtained though core-needle biopsy. Nevertheless,
only patients with an adequate specimen for immunohis-
tochemical examination were included. A further limita-
tion is that the follow-up period was not long enough for
thymic epithelial tumors.
In conclusion, the expression of ERCC1, BRCA1, and
TUBB3 tended to increase from low-grade to high-grade
thymic epithelial tumors. An expression of ERCC1, BRCA1,
and TUBB3 was correlated strongly with each other and were
significantly associated with a poor outcome in thymic epi-
thelial tumors. High-ERCC1 and TUBB3 expressions might
be associated with resistance to platinum- and taxane-based
chemotherapy, respectively.
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